Cargando…
COLAR: open-label clinical study of IL-6 blockade with tocilizumab for the treatment of immune checkpoint inhibitor-induced colitis and arthritis
BACKGROUND: Immune-related adverse events due to immune checkpoint inhibitors (ICIs) are not always effectively treated using glucocorticoids and it may negatively affect the antitumor efficacy of ICIs. Interventional studies of alternatives to glucocorticoids are lacking. We examined whether interl...
Autores principales: | Holmstroem, Rikke Boedker, Nielsen, Ole Haagen, Jacobsen, Søren, Riis, Lene Buhl, Theile, Susann, Bjerrum, Jacob Tveiten, Vilmann, Peter, Johansen, Julia Sidenius, Boisen, Mogens Karsbøl, Eefsen, Rikke Helene Løvendahl, Marie Svane, Inge, Nielsen, Dorte Lisbet, Chen, Inna Markovna |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9472120/ https://www.ncbi.nlm.nih.gov/pubmed/36096534 http://dx.doi.org/10.1136/jitc-2022-005111 |
Ejemplares similares
-
Tofacitinib and faecal microbiota transplantation in treating checkpoint inhibitor-induced enterocolitis: case report
por: Holmstroem, Rikke Boedker, et al.
Publicado: (2022) -
Randomised phase II trial of stereotactic body radiotherapy in combination with checkpoint inhibitors in metastatic castration-resistant prostate cancer (CheckPRO): a study protocol
por: Spindler, Nicklas Juel, et al.
Publicado: (2023) -
A Randomized Placebo-Controlled Phase 2 Study of Gemcitabine and Capecitabine with or without T-ChOS as Adjuvant Therapy in Patients with Resected Pancreatic Cancer (CHIPAC)
por: Theile, Susann, et al.
Publicado: (2022) -
Lipidomic Trajectories Characterize Delayed Mucosal Wound Healing in Quiescent Ulcerative Colitis and Identify Potential Novel Therapeutic Targets
por: Bjerrum, Jacob Tveiten, et al.
Publicado: (2022) -
Metabonomics in Gastroenterology and Hepatology
por: Bjerrum, Jacob Tveiten, et al.
Publicado: (2019)